Search

Your search keyword '"Bruzzese, Antonella"' showing total 188 results
Start Over Author "Bruzzese, Antonella"
188 results on '"Bruzzese, Antonella"'

4. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Stanzione, Gaia, additional, Zimbo, Annamaria, additional, Lugli, Elisabetta, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

5. Momelotinib in myelofibrosis

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Fragliasso, Valentina, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

6. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials.

Author

Martino, Enrica Antonia, Palmieri, Salvatore, Galli, Monica, Derudas, Daniele, Mina, Roberto, Della Pepa, Roberta, Zambello, Renato, Vigna, Ernesto, Bruzzese, Antonella, Mangiacavalli, Silvia, Zamagni, Elena, Califano, Catello, Musso, Maurizio, Conticello, Concetta, Cerchione, Claudio, Mele, Giuseppe, Di Renzo, Nicola, Offidani, Massimo, Tarantini, Giuseppe, and Casaluci, Gloria Margiotta

Subjects
CLINICAL trials, MULTIPLE myeloma, DEXAMETHASONE, OVERALL survival, PROGRESSION-free survival
Abstract

The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Selinexor in multiple myeloma

Author

Martino, Enrica Antonia, primary, Vigna, Ernesto, additional, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Torricelli, Federica, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

11. Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

12. Ivosidenib in acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Labanca, Caterina, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

13. Teclistamab‐cqyv in multiple myeloma

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

14. Tagraxofusp in myeloid malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

18. Teclistamab‐cqyv in multiple myeloma.

Author

Martino, Enrica Antonia, Bruzzese, Antonella, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
*MULTIPLE myeloma, *BISPECIFIC antibodies, *PLASMA cells, *PATIENT experience, *DISEASE relapse, *PLASMACYTOMA
Abstract

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta‐drug refractory patients continue to be the hard core of relapsed/refractory (RR) settings. Teclistamab‐cqyv is a humanized IgG4 antibody and a bispecific BCMA‐director CD3 T‐cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab‐cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti‐CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Tagraxofusp in myeloid malignancies.

Author

Bruzzese, Antonella, Martino, Enrica Antonia, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Imovilli, Annalisa, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
DIPHTHERIA toxin, RECOMBINANT molecules, INTERLEUKIN-3, ADP-ribosylation, DENDRITIC cells
Abstract

Tagraxofusp (or SL‐401) is a recombinant molecule composed of human interleukin‐3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease that is usually refractory to conventional chemotherapy. Tagraxofusp had an acceptable safety profile and high efficacy in early phase I/II studies on patients with BPDCN. Another phase II study confirmed the good response rates, resulting in Food and Drugs Administration and European Medicine Agency approval of tagraxofusp for the treatment of BPDCN. Considering its high efficacy and its manageable safety profile, tagraxofusp has been suddenly explored in other myeloid malignancies with high expression of cell surface CD123, both in monotherapy or combination strategies. The triplet tagraxofusp‐azacytidine‐venetoclax appears to be of particular interest among these combinations. Furthermore, combination strategies may be used to overcome tagraxofusp resistance. The downregulation of DPH1 (diphthamide biosynthesis 1), the enzyme responsible for the conversion of histidine 715 on eEF2 to diphthamide, which is then the direct target of ADP ribosylation DT, is typically associated with this resistance phenomenon. It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the success of tagraxofusp in BPDCN paved the way for its application even in other CD123‐positive malignancies. Nowadays, several ongoing trials are exploring the use of tagraxofusp in different myeloid neoplasms. This review aims to summarize the actual role of tagraxofusp in BPDCN and other CD123‐positive myeloid malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Terzi, Dario, additional, Greco, Sonia, additional, Martino, Enrica Antonia, additional, Vangeli, Valeria, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Labanca, Caterina, additional, Morelli, Rosellina, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Zinno, Francesco, additional, Mastroianni, Antonio, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

21. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials

Author

Gentile, Massimo, primary, Vigna, Ernesto, additional, Palmieri, Salvatore, additional, Galli, Monica, additional, Derudas, Daniele, additional, Mina, Roberto, additional, Pepa, Roberta Della, additional, Zambello, Renato, additional, Martino, Enrica Antonia, additional, Bruzzese, Antonella, additional, Mangiacavalli, Silvia, additional, Zamagni, Elena, additional, Califano, Catello, additional, Musso, Maurizio, additional, Conticello, Concetta, additional, Cerchione, Claudio, additional, Mele, Giuseppe, additional, Di Renzo, Nicola, additional, Offidani, Massimo, additional, Tarantini, Giuseppe, additional, Casaluci, Gloria Margiotta, additional, Rago, Angela, additional, Ria, Roberto, additional, Uccello, Giuseppina, additional, Barilà, Gregorio, additional, Palumbo, Gaetano, additional, Pompa, Alessandra, additional, Vincelli, Donatella, additional, Brunori, Marino, additional, Accardi, Fabrizio, additional, Amico, Valeria, additional, Amendola, Angela, additional, Fontana, Raffaele, additional, Bongarzoni, Velia, additional, Rossini, Bernardo, additional, Cotzia, Emilia, additional, Gozzetti, Alessandro, additional, Rizzi, Rita, additional, Sgherza, Nicola, additional, Ferretti, Eleonora, additional, Bertuglia, Giuseppe, additional, Nappi, Davide, additional, Petrucci, Maria Teresa, additional, Di Raimondo, Francesco, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Musto, Pellegrino, additional

Published
2023
Full Text
View/download PDF

22. Glasdegib for the treatment of acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Fimognari, Filippo, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

24. Zanubrutinib for the treatment of chronic lymphocytic leukemia

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

25. Belantamab mafodotin in multiple myeloma

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Iaccino, Enrico, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Mimmi, Selena, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

26. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Mauro, Francesca Romana, additional, Laurenti, Luca, additional, Reda, Gianluigi, additional, Moia, Riccardo, additional, Condoluci, Adalgisa, additional, Vincelli, Iolanda, additional, Chiarenza, Annalisa, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Bruzzese, Antonella, additional, Mezzatesta, Sabrina, additional, Laureana, Roberta, additional, Cutrona, Giovanna, additional, Di Raimondo, Francesco, additional, Fronza, Gilberto, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Rossi, Francesca Maria, additional, Olivieri, Jacopo, additional, Zaja, Francesco, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Del Principe, Maria Ilaria, additional, Ilariucci, Fiorella, additional, Del Poeta, Giovanni, additional, Ferrarini, Manlio, additional, Neri, Antonino, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

27. Myelodysplastic syndromes with ring sideroblasts.

Author

Bruzzese, Antonella, Vigna, Ernesto, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Bova, Carlo, Barbato, Angelo, Filippelli, Gianfranco, Capodanno, Isabella, Neri, Antonino, Morabito, Fortunato, and Gentile, Massimo

Subjects
MYELODYSPLASTIC syndromes, CLINICAL trials, HEMATOPOIETIC stem cells, MUTANT proteins, CHIMERIC proteins, DECITABINE
Abstract

Myelodysplastic syndromes (MDS) are acquired bone marrow malignant disorders characterized by ineffective hematopoiesis, resulting from a complex interaction between genetic and epigenetic mutations, alterations of the marrow microenvironment, and the immune system. In 2001, the World Health Organization (WHO) proposed a classification that integrates morphologic and genetic information, considering the MDS with ring sideroblasts (MDS‐RS) as a distinct entity. Considering the strong association between MDS‐RS and SF3B1 mutation and its importance in the development of MDS, the last WHO classification replaced the prior entity of MDS‐RS with MDS with SF3B1 mutation. Several studies were performed to explore this genotype‐phenotype correlation. Mutant SF3B1 protein deregulates the expression of genes implicated in developing hematopoietic stem and progenitor cells. Of paramount importance are PPOX and ABCB7 involved in iron metabolism. Another essential role in hemopoiesis is played by the transforming growth factor‐beta (TGF‐β) receptor. This gene exerts its effects on SMAD pathways, regulating hematopoiesis through effects on balancing proliferation and apoptosis cell inactivity, differentiation, and migration. Luspatercept (ACE‐536) is a soluble fusion protein that inhibits molecules in the TGF‐β superfamily. Since its structure resembles the TGF‐β family receptor, it catches TGF‐β superfamily ligands before binding to the receptor, resulting in reduced activation of SMAD signaling, thus enabling erythroid maturation. Luspatercept was investigated in the phase III trial MEDALIST, showing promising efficacy in treating anemia compared to placebo. Nowadays, further studies are needed to explore the real potential of luspatercept, investigating the biological features likely associated with treatment response, the potential use in combination treatments, and its role in the treatment of naïve MDS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Acalabrutinib in chronic lymphocytic leukemia

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Vigna, Ernesto, additional, Iaccino, Enrico, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Filippelli, Gianfranco, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

32. Isatuximab in multiple myeloma

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Iaccino, Enrico, additional, Mendicino, Francesco, additional, Mimmi, Selena, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

33. Venetoclax in acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

34. Iron chelation therapy

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Bova, Carlo, additional, Filippelli, Gianfranco, additional, Capodanno, Isabella, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Gentile, Massimo, additional, and Vigna, Ernesto, additional

Published
2023
Full Text
View/download PDF

36. CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.

Author

Michele Malagola, Raffaella Greco, Stella Santarone, Anna Paola Iori, Luisa Quatrocchi, Walter Barberi, Bruzzese Antonella, Salvatore Leotta, Alessandra Carotti, Antonio Pierini, Simon Bernardi, Enrico Morello, Nicola Polverelli, Alessandro Turra, Federica Cattina, Lisa Gandolfi, Benedetta Rambaldi, Francesca Lorentino, Francesca Serio, Annalisa Natale, Giuseppe Milone, Andrea Velardi, Robin Foà, Fabio Ciceri, Domenico Russo, and Jacopo Peccatori

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

CMV represents one of the most serious life-threatening complications of allogeneic stem cell transplantaion (allo-SCT). Pre-emptive treatment is highly effective, but toxicity and repetitive reactivation of CMV represent a major challenge in the clinical practice. The use of anti-CMV specific immunoglobulins (Megalotect) is controversial. We retrospectively collected data on 92 patients submitted to allo-SCT for hematological malignancies, in whom Megalotect was used either for prophylaxis (n=14) or with pre-emptive therapy (n=78). All the patients were considered at high-risk of developing CMV reactivation and CMV disease. The treatment was well tolerated, with no reported infusion reactions, nor other adverse events. None of the 14 cases treated with Megalotect as prophylaxis developed CMV reactivation. 51/78 (65%) patients who received Megalotect during pre-emptive treatment achieved complete clearance of CMV viremia, and 14/51 patients (29%) developed a breakthroug CMV infection. 7/78 patients (9%) developed CMV disease. The projected 1-year OS, 1-year TRM and 1-year RR is 74%, 15% and 19%, respectively. No differences were observed in terms of OS, TRM and RR by comparing patients who achieved a complete response after treatment versus those who did not.. These retrospective data suggest that Megalotect is safe and well tolerated. When used as prophylaxis, no CMV reactivation was recorded. We have no conclusive data regarding its efficacy in reducing the cumulative dose of anti-CMV specific drugs in the pre-emptive setting. Further prospective trials are warrented to identify the best setting of patients who can benefit from Megalotect alone or in addition to anti-CMV specific drugs.

Published
2019
Full Text
View/download PDF

39. Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Mazzulla, Rosanna, additional, De Rose, Silvia, additional, Cozza, Pietro Pasquale, additional, Bova, Carlo, additional, Filippelli, Gianfranco, additional, Zinno, Francesco, additional, Morelli, Michele, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

40. Elotuzumab in multiple myeloma

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Iaccino, Enrico, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Filippelli, Gianfranco, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

41. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

Author

Morabito, Fortunato, primary, Zamagni, Elena, additional, Conticello, Concetta, additional, Pavone, Vincenzo, additional, Palmieri, Salvatore, additional, Bringhen, Sara, additional, Galli, Monica, additional, Mangiacavalli, Silvia, additional, Derudas, Daniele, additional, Rossi, Elena, additional, Ria, Roberto, additional, Catalano, Lucio, additional, Tacchetti, Paola, additional, Mele, Giuseppe, additional, Vincelli, Iolanda Donatella, additional, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Bruzzese, Antonella, additional, Mendicino, Francesco, additional, Botta, Cirino, additional, Mele, Anna, additional, Pantani, Lucia, additional, Rocchi, Serena, additional, Garibaldi, Bruno, additional, Cascavilla, Nicola, additional, Ballanti, Stelvio, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Falcone, Antonetta Pia, additional, Cangialosi, Clotilde, additional, Reddiconto, Giovanni, additional, Farina, Giuliana, additional, Barone, Marialucia, additional, Rizzello, Ilaria, additional, Iaccino, Enrico, additional, Mimmi, Selena, additional, Curci, Paola, additional, Gamberi, Barbara, additional, Musto, Pellegrino, additional, De Stefano, Valerio, additional, Musso, Maurizio, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Di Raimondo, Francesco, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Neri, Antonino, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

43. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Author

Bruzzese, Antonella, primary, Derudas, Daniele, additional, Galli, Monica, additional, Martino, Enrica Antonia, additional, Rocco, Stefano, additional, Conticello, Concetta, additional, Califano, Catello, additional, Giuliani, Nicola, additional, Mangiacavalli, Silvia, additional, Farina, Giuliana, additional, Lombardo, Alessandra, additional, Brunori, Marino, additional, Rossi, Elena, additional, Antonioli, Elisabetta, additional, Ria, Roberto, additional, Zambello, Renato, additional, Di Renzo, Nicola, additional, Mele, Giuseppe, additional, Marcacci, Gianpaolo, additional, Pietrantuono, Giuseppe, additional, Palumbo, Gaetano, additional, Cascavilla, Nicola, additional, Cerchione, Claudio, additional, Belotti, Angelo, additional, Criscuolo, Clelia, additional, Uccello, Giuseppina, additional, Curci, Paola, additional, Vigna, Ernesto, additional, Mendicino, Francesco, additional, Iaccino, Enrico, additional, Mimmi, Selena, additional, Botta, Cirino, additional, Vincelli, Donatella, additional, Sgherza, Nicola, additional, Bonalumi, Angela, additional, Cupelli, Luca, additional, Stocchi, Raffaella, additional, Martino, Massimo, additional, Ballanti, Stelvio, additional, Gangemi, Dominella, additional, Gagliardi, Alfredo, additional, Gamberi, Barbara, additional, Pompa, Alessandra, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Consoli, Ugo, additional, Bringhen, Sara, additional, Zamagni, Elena, additional, Patriarca, Francesca, additional, De Stefano, Valerio, additional, Di Raimondo, Francesco, additional, Palmieri, Salvatore, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

44. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

Author

Morabito, Fortunato, primary, Zamagni, Elena, additional, Conticello, Concetta, additional, Pavone, Vincenzo, additional, Palmieri, Salvatore, additional, Bringhen, Sara, additional, Galli, Monica, additional, Mangiacavalli, Silvia, additional, Derudas, Daniele, additional, Rossi, Elena, additional, Ria, Roberto, additional, Catalano, Lucio, additional, Tacchetti, Paola, additional, Mele, Giuseppe, additional, Donatella Vincelli, Iolanda, additional, Antonia Martino, Enrica, additional, Vigna, Ernesto, additional, Botta, Cirino, additional, Bruzzese, Antonella, additional, Mele, Anna, additional, Pantani, Lucia, additional, Rocchi, Serena, additional, Garibaldi, Bruno, additional, Cascavilla, Nicola, additional, Ballanti, Stelvio, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Pia Falcone, Antonetta, additional, Cangialosi, Clotilde, additional, Reddiconto, Giovanni, additional, Farina, Giuliana, additional, Barone, Marialucia, additional, Rizzello, Ilaria, additional, Musto, Pellegrino, additional, De Stefano, Valerio, additional, Musso, Maurizio, additional, Teresa Petrucci, Maria, additional, Offidani, Massimo, additional, Neri, Antonino, additional, Di Renzo, Nicola, additional, Di Raimondo, Francesco, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

45. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.

Author

Martino, Enrica Antonia, Conticello, Concetta, Zamagni, Elena, Pavone, Vincenzo, Palmieri, Salvatore, Musso, Maurizio, Tacchetti, Paola, Mele, Anna, Catalano, Lucio, Vigna, Ernesto, Bruzzese, Antonella, Mendicino, Francesco, Botta, Cirino, Vincelli, Iolanda Donatella, Farina, Giuliana, Barone, Marialucia, Cangialosi, Clotilde, Mancuso, Katia, Rizziello, Ilaria, and Rocchi, Serena

Subjects
MULTIPLE myeloma, CLINICAL trials, SALVAGE therapy, LENALIDOMIDE, PROGRESSION-free survival, ARRHYTHMIA, HEART failure
Abstract

In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet are still the object of investigation by many groups to confirm ASPIRE results in the setting of RRMM treated in real‐life who don't meet trial restrictive inclusion criteria. Therefore, we report a retrospective multicenter analysis of 600 RRMM patients treated with KRd between December 2015 and December 2018. The median age was 64 years (range 33–85), and the median number of previous therapies was two (range 1–11). After a median of 11 KRd cycles, the overall response rate was 79.9%. The median progression‐free survival (PFS) was 22 months, and the 2‐year probability of PFS was 47.6%. Creatinine clearance<30 ml/min, >1 line of previous therapy, and high‐risk FISH were all associated with a poor prognosis in multivariate analysis. The median overall survival (OS) was 34.8 months; the 2‐year probability of OS was 63.5%. At multivariate analysis, creatinine clearance<30 ml/min, >1 line of previous therapy, and high‐risk FISH were significantly associated with poor prognosis. After a median follow‐up of 16 months (range 1–50), 259 withdrew from therapy. The main discontinuation reason was progressive disease (81.8%). Seventy‐four patients (12.3%) discontinued therapy for toxicity. The most frequent side effects were hematological (anemia 49.3%, neutropenia 42.7%, thrombocytopenia 42.5%) and cardiovascular (hypertension 14.5%, heart failure 2.5%, arrhythmias 3.6%). Our study confirms the safety and efficacy of KRd in the real‐life setting of RRMM patients and encourages its use in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Elotuzumab in multiple myeloma

Author

Bruzzese, Antonella, Martino, Enrica Antonia, Vigna, Ernesto, Iaccino, Enrico, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Filippelli, Gianfranco, Neri, Antonino, Morabito, Fortunato, and Gentile, Massimo

Published
2023
Full Text
View/download PDF

49. The game of participation in Amsterdam East:an alternative to the neoliberal or a neoliberal alternative

Author

Kovacs, Z., Smets, Peer, Ghorashi, Halleh, Fisker, Jens Kaae, Chiappini, Letizia, Pugalis, Lee, Bruzzese, Antonella, Fisker, Jens Kaae, Chiappini, Letizia, Pugalis, Lee, Bruzzese, Antonella, Sociology, and Identities, Diversity and Inclusion (IDI)

Subjects
Community building, media_common.quotation_subject, 05 social sciences, 0211 other engineering and technologies, 0507 social and economic geography, 021107 urban & regional planning, Citizen journalism, 02 engineering and technology, Gentrification, Social mobility, Democracy, Politics, Political science, Political economy, Agency (sociology), Voluntarism (action), 050703 geography, media_common
Abstract

With a point of departure in a Bourdieusian framework, the chapter studies dynamics between participatory policymaking and the citizenry’s political agency in a gentrifying neighborhood in Amsterdam East. The analysis shows that gentrifiers, through their community building efforts and resourcefulness, are capable of creating political opportunities for the citizenry to become co-producers in the field of local policy implementation; this enabled social mobility and a creation of a civic democratic culture. At the same time, this alternative field of participation is not immune to reproducing effects related to gentrification and voluntarism.

Published
2019

50. Urban Questions in the Times of Coronavirus. Responding to the Crisis of Public Space

Author

Radović, Darko, primary, Boontharm, Davisi, additional, Klomp, Pieter, additional, Bruzzese, Antonella, additional, Cairns, Stephen, additional, Fikfak, Alenka, additional, Kuma, Kengo, additional, Maturana, Beatriz, additional, Medina, Ana, additional, Oguma, Eiji, additional, Sim, David, additional, Sintusingha, Sidh, additional, and Verhoeven, Saline, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results